ArticleJournal of tissue engineering and regenerative medicine2012
Phenotypic and functional characterization of human bone marrow stromal cells in hollow-fibre bioreactors.
Article in Journal of tissue engineering and regenerative medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Investigating dynamics of lentiviral vector secretion from HEK293T producer cells using a fractionated perfusion system.Biotechnology journal · 2024Article
- Dynamics of Ex Vivo Mesenchymal Stromal Cell Potency under Continuous Perfusion.International journal of molecular sciences · 2023Article
- Convergence of Cell Pharmacology and Drug Delivery.Stem cells translational medicine · 2019Article
- Biomanufacturing for clinically advanced cell therapies.Nature biomedical engineering · 2018Review
- Modelling mesenchymal stromal cell growth in a packed bed bioreactor with a gas permeable wall.PloS one · 2018Article
- An engineered biomarker system to monitor and modulate immune clearance of cell therapies.Cytotherapy · 2017Article
- Artificial Bone via Bone Tissue Engineering: Current Scenario and Challenges.Tissue engineering and regenerative medicine · 2017Review
- Secreted factors from bone marrow stromal cells upregulate IL-10 and reverse acute kidney injury.Stem cells international · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The transplantation of human bone marrow stromal cells (BMSCs) is a novel immunotherapeutic approach that is currently being explored in many clinical settings. Evidence suggests that the efficacy of cell transplantation is directly associated with soluble factors released by human BMSCs. In order to harness these secreted factors, we integrated BMSCs into large-scale hollow-fibre bioreactor devices in which the cells, separated by a semipermeable polyethersulphone (PES) membrane, can directly and continuously release therapeutic factors into the blood stream. BMSCs were found to be rapidly adherent and exhibited long-term viability on PES fibres. The cells also preserved their immunophenotype under physiological fluid flow rates in the bioreactor, and exhibited no signs of differentiation during device operation, but still retained the capacity to differentiate into osteoblastic lineages. BMSC devices released growth factors and cytokines at comparable levels on a per-cell basis to conventional cell culture platforms. Finally, we utilized a potency assay to demonstrate the therapeutic potential of the collected secreted factors from the BMSC devices. In summary, we have shown that culturing BMSCs in a large-scale hollow-fibre bioreactor is feasible without deleterious effects on phenotype, thus providing a platform for collecting and delivering the paracrine secretions of these cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.